Copyright (c) 2018 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Spectrophotometric Determination of Aprepitant in Bulk and Pharmaceutical Dosage Forms Using Bromocresol Green as Chromogenic Reagent
Corresponding Author(s) : Maliheh Barazandeh Tehrani
Asian Journal of Chemistry,
Vol. 30 No. 6 (2018): Vol 30 Issue 6
Abstract
Aprepitant is a substance P/neurokinin 1 receptor antagonist, which is used for preventing both acute and delayed emesis. In the present study a simple and accurate spectrophotometric method has been developed for quantitative determination of aprepitant in bulk and pharmaceutical dosage forms based on the formation of ion-pair complex between the drug and bromocresol green. The 1:1 yellow colour aprepitant-bromocresol green (BCG) ion-pair complex was formed in buffer solution at pH = 4, extracted with chloroform and measured at 413 nm. The optimum reaction conditions such as pH, reagent amount, extracting solvent and stoichiometry of the ion-pair complex were investigated. The developed method showed excellent linearity over the concentration range of 150-500 μg/mL with acceptable correlation coefficient (r2 = 0.998), precision (CV < 3.67 %) and accuracy (Error < 3.46 %). The proposed method was successfully applied for determination of aprepitant in capsule dosage forms and no interference from excipients was observed.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- J. Liu, M. Zou, H. Piao, Y. Liu, B. Tang, Y. Gao, N. Ma and G. Cheng, Molecules, 20, 11345 (2015); https://doi.org/10.3390/molecules200611345.
- P.R. Bhandari, J. Adv. Pharm. Technol. Res., 3, 202 (2012); https://doi.org/10.4103/2231-4040.104710.
- C.N. Rittenberg, Clin. J. Oncol. Nurs., 6, 103 (2002); https://doi.org/10.1188/02.CJON.103-104.
- C. Girish and S. Manikandan, Indian J. Cancer, 44, 25 (2007); https://doi.org/10.4103/0019-509X.31164.
- L.A. Sorbera, J. Castaner, M. Bayes and J. Silvestre, J. Drugs Future, 27, 211 (2002); https://doi.org/10.1358/dof.2002.027.03.661047.
- P.V.D.L.S. Ravi Prakash, J. Bioequiv. Bioavailab., 5, 110 (2013); https://doi.org/10.4172/jbb.1000143.
- D. Wu, D.J. Paul, X. Zhao, S.D. Douglas and J.S. Barrett, J. Pharm. Biomed. Anal., 49, 739 (2009); https://doi.org/10.1016/j.jpba.2008.12.005.
- I.A. Darwish, I.H. Refaat, H.F. Askal and M.A. Marzouq, J. AOAC Int., 89, 334 (2006).
- K.K. Chaitanya, D.G. Sankar, D.S. Israel and Ch. Narasimha Kumar, Der. Pharma Chemica, 5, 39 (2013).
- V.K. Kumar, N.A. Raju and S.H. Begum, Res. J. Pharm. Technol., 2, 412 (2009).
- A. Levent and Z. Senturk, Comb. Chem. High Throughput Screen., 13, 675 (2010); https://doi.org/10.2174/138620710791920383.
- M.N. Patel, B.S. Bhatt, D.S. Gandhi, P.A. Dosi and P.A. Parmar, J. Anal. Chem., 67, 655 (2012); https://doi.org/10.1134/S1061934812050103.
- D.R. Chaple and K.P. Bhusari, Asian J. Chem., 22, 2593 (2010).
- E. Souri, D. Hemmatianpour, M. Amanlou and M.B. Tehrani, Res. J. Pharm. Biol. Chem. Sci., 5, 373 (2014).
- M. Amanlou, A.G. Moghadam, M.B. Tehrani and E. Souri, Iran. J. Pharm. Res., 13, 81 (2014).
- M. Amanlou, M.H. Nazlou, H. Azizian, E. Souri and H. Farsam, Anal. Lett., 40, 3267 (2007); https://doi.org/10.1080/00032710701672384.
- E. Souri, A. Kaboodari, N. Adib and M. Amanlou, Daru, 21, 12 (2013); https://doi.org/10.1186/2008-2231-21-12.
- A. Al-Haj Sakur and H. Fael, Int. J. Acad. Sci. Res., 4, 9 (2016).
- USP 29 NF 24, United States Pharmacopoeia. U.S. Pharmacopeial Convention, Inc., Rockville, MD (2006).
- BP 2003, British Pharmacopoeia. The Stationary Office under License from the Controller of Her Majesty’s Stationary Office, UK, vol. I and II (2003).
References
J. Liu, M. Zou, H. Piao, Y. Liu, B. Tang, Y. Gao, N. Ma and G. Cheng, Molecules, 20, 11345 (2015); https://doi.org/10.3390/molecules200611345.
P.R. Bhandari, J. Adv. Pharm. Technol. Res., 3, 202 (2012); https://doi.org/10.4103/2231-4040.104710.
C.N. Rittenberg, Clin. J. Oncol. Nurs., 6, 103 (2002); https://doi.org/10.1188/02.CJON.103-104.
C. Girish and S. Manikandan, Indian J. Cancer, 44, 25 (2007); https://doi.org/10.4103/0019-509X.31164.
L.A. Sorbera, J. Castaner, M. Bayes and J. Silvestre, J. Drugs Future, 27, 211 (2002); https://doi.org/10.1358/dof.2002.027.03.661047.
P.V.D.L.S. Ravi Prakash, J. Bioequiv. Bioavailab., 5, 110 (2013); https://doi.org/10.4172/jbb.1000143.
D. Wu, D.J. Paul, X. Zhao, S.D. Douglas and J.S. Barrett, J. Pharm. Biomed. Anal., 49, 739 (2009); https://doi.org/10.1016/j.jpba.2008.12.005.
I.A. Darwish, I.H. Refaat, H.F. Askal and M.A. Marzouq, J. AOAC Int., 89, 334 (2006).
K.K. Chaitanya, D.G. Sankar, D.S. Israel and Ch. Narasimha Kumar, Der. Pharma Chemica, 5, 39 (2013).
V.K. Kumar, N.A. Raju and S.H. Begum, Res. J. Pharm. Technol., 2, 412 (2009).
A. Levent and Z. Senturk, Comb. Chem. High Throughput Screen., 13, 675 (2010); https://doi.org/10.2174/138620710791920383.
M.N. Patel, B.S. Bhatt, D.S. Gandhi, P.A. Dosi and P.A. Parmar, J. Anal. Chem., 67, 655 (2012); https://doi.org/10.1134/S1061934812050103.
D.R. Chaple and K.P. Bhusari, Asian J. Chem., 22, 2593 (2010).
E. Souri, D. Hemmatianpour, M. Amanlou and M.B. Tehrani, Res. J. Pharm. Biol. Chem. Sci., 5, 373 (2014).
M. Amanlou, A.G. Moghadam, M.B. Tehrani and E. Souri, Iran. J. Pharm. Res., 13, 81 (2014).
M. Amanlou, M.H. Nazlou, H. Azizian, E. Souri and H. Farsam, Anal. Lett., 40, 3267 (2007); https://doi.org/10.1080/00032710701672384.
E. Souri, A. Kaboodari, N. Adib and M. Amanlou, Daru, 21, 12 (2013); https://doi.org/10.1186/2008-2231-21-12.
A. Al-Haj Sakur and H. Fael, Int. J. Acad. Sci. Res., 4, 9 (2016).
USP 29 NF 24, United States Pharmacopoeia. U.S. Pharmacopeial Convention, Inc., Rockville, MD (2006).
BP 2003, British Pharmacopoeia. The Stationary Office under License from the Controller of Her Majesty’s Stationary Office, UK, vol. I and II (2003).